A replication-incompetent Rift Valley fever vaccine

Chimeric virus-like particles protect mice and rats against lethal challenge

Robert B. Mandell, Ramesh Koukuntla, Laura J K Mogler, Andrea K. Carzoli, Alexander Freiberg, Michael R. Holbrook, Brian K. Martin, William R. Staplin, Nicholas N. Vahanian, Charles J. Link, Ramon Flick

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins GN and GC, nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans and livestock. Long-lasting humoral and cellular immune responses are demonstrated in a mouse model by the analysis of neutralizing antibody titers and cytokine secretion profiles. Vaccine efficacy studies were performed in mouse and rat lethal challenge models resulting in high protection rates. Taken together, these results demonstrate that replication-incompetent chimeric RVF VLPs are an efficient RVFV vaccine candidate.

Original languageEnglish (US)
Pages (from-to)187-198
Number of pages12
JournalVirology
Volume397
Issue number1
DOIs
StatePublished - Feb 5 2010

Fingerprint

Virus-Like Particle Vaccines
Rift Valley Fever
Vaccines
Rift Valley fever virus
Virion
Moloney murine leukemia virus
gag Gene Products
Nucleoproteins
Viral Antigens
Livestock
Virus Diseases
Humoral Immunity
Neutralizing Antibodies
Cellular Immunity
Immune System
Glycoproteins
Cytokines

Keywords

  • Chimeric
  • Rift Valley fever virus
  • Vaccine
  • Virus-like particle

ASJC Scopus subject areas

  • Virology

Cite this

A replication-incompetent Rift Valley fever vaccine : Chimeric virus-like particles protect mice and rats against lethal challenge. / Mandell, Robert B.; Koukuntla, Ramesh; Mogler, Laura J K; Carzoli, Andrea K.; Freiberg, Alexander; Holbrook, Michael R.; Martin, Brian K.; Staplin, William R.; Vahanian, Nicholas N.; Link, Charles J.; Flick, Ramon.

In: Virology, Vol. 397, No. 1, 05.02.2010, p. 187-198.

Research output: Contribution to journalArticle

Mandell, RB, Koukuntla, R, Mogler, LJK, Carzoli, AK, Freiberg, A, Holbrook, MR, Martin, BK, Staplin, WR, Vahanian, NN, Link, CJ & Flick, R 2010, 'A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge', Virology, vol. 397, no. 1, pp. 187-198. https://doi.org/10.1016/j.virol.2009.11.001
Mandell, Robert B. ; Koukuntla, Ramesh ; Mogler, Laura J K ; Carzoli, Andrea K. ; Freiberg, Alexander ; Holbrook, Michael R. ; Martin, Brian K. ; Staplin, William R. ; Vahanian, Nicholas N. ; Link, Charles J. ; Flick, Ramon. / A replication-incompetent Rift Valley fever vaccine : Chimeric virus-like particles protect mice and rats against lethal challenge. In: Virology. 2010 ; Vol. 397, No. 1. pp. 187-198.
@article{541ef57e802240f590563e5dc697ab10,
title = "A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge",
abstract = "Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins GN and GC, nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans and livestock. Long-lasting humoral and cellular immune responses are demonstrated in a mouse model by the analysis of neutralizing antibody titers and cytokine secretion profiles. Vaccine efficacy studies were performed in mouse and rat lethal challenge models resulting in high protection rates. Taken together, these results demonstrate that replication-incompetent chimeric RVF VLPs are an efficient RVFV vaccine candidate.",
keywords = "Chimeric, Rift Valley fever virus, Vaccine, Virus-like particle",
author = "Mandell, {Robert B.} and Ramesh Koukuntla and Mogler, {Laura J K} and Carzoli, {Andrea K.} and Alexander Freiberg and Holbrook, {Michael R.} and Martin, {Brian K.} and Staplin, {William R.} and Vahanian, {Nicholas N.} and Link, {Charles J.} and Ramon Flick",
year = "2010",
month = "2",
day = "5",
doi = "10.1016/j.virol.2009.11.001",
language = "English (US)",
volume = "397",
pages = "187--198",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A replication-incompetent Rift Valley fever vaccine

T2 - Chimeric virus-like particles protect mice and rats against lethal challenge

AU - Mandell, Robert B.

AU - Koukuntla, Ramesh

AU - Mogler, Laura J K

AU - Carzoli, Andrea K.

AU - Freiberg, Alexander

AU - Holbrook, Michael R.

AU - Martin, Brian K.

AU - Staplin, William R.

AU - Vahanian, Nicholas N.

AU - Link, Charles J.

AU - Flick, Ramon

PY - 2010/2/5

Y1 - 2010/2/5

N2 - Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins GN and GC, nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans and livestock. Long-lasting humoral and cellular immune responses are demonstrated in a mouse model by the analysis of neutralizing antibody titers and cytokine secretion profiles. Vaccine efficacy studies were performed in mouse and rat lethal challenge models resulting in high protection rates. Taken together, these results demonstrate that replication-incompetent chimeric RVF VLPs are an efficient RVFV vaccine candidate.

AB - Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins GN and GC, nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans and livestock. Long-lasting humoral and cellular immune responses are demonstrated in a mouse model by the analysis of neutralizing antibody titers and cytokine secretion profiles. Vaccine efficacy studies were performed in mouse and rat lethal challenge models resulting in high protection rates. Taken together, these results demonstrate that replication-incompetent chimeric RVF VLPs are an efficient RVFV vaccine candidate.

KW - Chimeric

KW - Rift Valley fever virus

KW - Vaccine

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=73949093570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949093570&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2009.11.001

DO - 10.1016/j.virol.2009.11.001

M3 - Article

VL - 397

SP - 187

EP - 198

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -